Archive: 8/09/2015

Study finds key GSK-Theravance lung drug didn't extend lives

A closely watched study of GlaxoSmithKline plc's Breo Ellipta respiratory treatment failed to prove that it extends patients' lives, denying the drugmaker a much-needed marketing edge in its most lucrative—but declining—medicine ...

page 1 from 11